While the efficacy of these three TKIs including overall response rate (ORR), duration of response (DOR), and median progression‐free survival (PFS) is generally reported in aggregate, upon closer examination, the ORR varies significantly by tumor types especially when treated with entrectinib for NTRK+ tumors and selpercatinib for RET+ tumors with the lowest ORRs reported among both NTRK+ [8] and RET+ colorectal adenocarcinoma (CRC) [9] (summarized in Table S1). The gene discussed is RET; the disease is neoplasm.